Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean M. Franchi Sells 2,000 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean M. Franchi sold 2,000 shares of the stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $57.50, for a total transaction of $115,000.00. Following the sale, the chief financial officer directly owned 65,530 shares of the company's stock, valued at $3,767,975. The trade was a 2.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Disc Medicine Stock Performance

Disc Medicine stock traded up $0.83 during mid-day trading on Monday, hitting $57.74. 235,086 shares of the company's stock traded hands, compared to its average volume of 338,655. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $68.73. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $50.05 and a 200 day moving average price of $51.61. The company has a market cap of $2.00 billion, a PE ratio of -14.73 and a beta of 0.76.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Analyst Ratings Changes

IRON has been the topic of several research reports. Cantor Fitzgerald raised their price target on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. HC Wainwright restated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Thursday, July 3rd. Morgan Stanley started coverage on shares of Disc Medicine in a report on Thursday, July 3rd. They issued an "overweight" rating and a $85.00 target price on the stock. Raymond James Financial started coverage on shares of Disc Medicine in a report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 target price on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday, June 16th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $96.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. Sterling Capital Management LLC boosted its stake in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine in the 4th quarter valued at $40,000. Amalgamated Bank boosted its position in shares of Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after purchasing an additional 219 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Disc Medicine by 13,428.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 947 shares of the company's stock worth $47,000 after acquiring an additional 940 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.